Conduit Pharmaceuticals and Charles River Laboratories have announced a partnership to evaluate AZD1656, a glucokinase activator, in a preclinical model of  systemic lupus erythematosus (SLE). This collaboration aims to generate high-quality preclinical data to guide the development of AZD1656 for autoimmune disorders, specifically SLE and lupus nephritis (LN).

Ahead of the phase II trial, Conduit will leverage Charle River’s expertise in immunology and preclinical research to refine study parameters, improve data quality and increase the probability for trial success. This study will focus on AZD1656’s potential to regulate the immune system, reduce inflammation, and slow disease progression in lupus. Researchers believe this preclinical evaluation will provide critical insights into how AZD1656 works and inform future clinical trial design. If successful, this approach could lead to new treatment options for people living with lupus.

Continue to follow the Lupus Foundation of America for updates on lupus drug developments and clinical trials. 

Read the announcement